USA flag logo/image

An Official Website of the United States Government

Transmucosal Intra-Oral Drug Delivery System for THC

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
66462
Program Year/Program:
2003 / STTR
Agency Tracking Number:
GM067304
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ELSOHLY LABORATORIES, INC.
5 INDUSTRIAL PARK DR OXFORD, MS 38655-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2003
Title: Transmucosal Intra-Oral Drug Delivery System for THC
Agency: HHS
Contract: 1R41GM067304-01
Award Amount: $99,986.00
 

Abstract:

DESCRIPTION (provided by applicant): The overall goal of this research project is to develop an effective, hot-melt extruded "Transmucosal Matrix Patch" (TMP) as a delivery system for Delta-9-Tetrahydrocannabinol (THC). THC will be incorporated into a stable, bioadhesive drug delivery system that is applied to a subject's buccal or labial oral mucosa. The controlled release of THC is delivered to the systemic circulation of the subject via a bio-erodable polymer matrix. This project will be accomplished through a plan of work to achieve the following specific aims: 1. Formulate and produce preliminary TMP systems 2. Evaluate preliminary systems, develop and optimize lead formulations 3. Hot-melt extrude, die-cut and package lead system formulations 4. Test and evaluate bioadhesive properties of TMP systems 5. Conduct stability studies of systems and finalize optimal TMP systems 6. Test final TMP formulations in animal models Successful incorporation of THC into a hot-melt extruded system as an alternate, more efficient method of delivery will have a tremendous impact on many chronically ill patients, such as those infected with the HIV virus or those undergoing chemotherapy. This novel drug delivery system for THC could also provide relief for those patients suffering from conditions known to be ameliorated by THC, such as glaucoma, migraines, rheumatic and osteo-arthritis, muscle dysfunction associated with multiple sclerosis, alcohol and other chemical dependence withdrawal symptoms, extreme stress, depression, asthma and epileptic seizures.

Principal Investigator:

Mahmoud A. Elsohly
6622362609
ELIMAE@WATERVALLEY.NET

Business Contact:

Mahmoud Elsohly
6622362609
Small Business Information at Submission:

Elsohly Laboratories, Inc.
5 INDUSTRIAL PARK DR 5 INDUSTRIAL PARK DR Oxford, MS 38655

EIN/Tax ID: 640712325
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
UNIVERSITY OF MISSISSIPPI
P.O. BOX 907
UNIVERSITY, MS 38677
RI Type: Nonprofit college or university